DIRECTOR OF THE JENNER INSTITUTE, LAKSHMI MITTAL & FAMILY PROFESSOR OF VACCINOLOGY, PROFESSOR OF HUMAN GENETICS
Vaccines for malaria and other major diseases
Adrian V. S. Hill KBE, FRCP, FRS is the Lakshmi Mittal Professor of Vaccinology and Director of the Jenner Institute at Oxford University. In 2005 he founded the Jenner Institute at Oxford, which is now one of the largest academic vaccine centres globally with clinical-stage vaccine programmes against fifteen diseases.
His current lead malaria vaccine, R21 in matrix-M adjuvant, has shown high efficacy in clinical trials in the UK and Africa (Lancet. 2021;397:1809-1818) and could be the first widely used vaccine to impact on the great disease burden of malaria in Africa.
In Q1 2020, the Jenner Institute initiated a major effort towards rapid development of a COVID-19 vaccine which in collaboration with AstraZeneca is now in world-wide pandemic deployment.
He has published over 600 research papers with 60,000 citations and co-founded several spin-off companies. He is a Fellow of the UK Academy of Medical Sciences, the Royal College of Physicians and the Royal Society.
Identification of host–pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank
Mentzer AJ. et al, (2022), Nature Communications, 13
Production of a high purity, C‐tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in
under cGMP conditions
Mukhopadhyay E. et al, (2022), Biotechnology and Bioengineering, 119, 2784 - 2793
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Madhavan M. et al, (2022), eBioMedicine, 104298 - 104298
Genome-wide association study of leprosy in Malawi and Mali.
Gilchrist JJ. et al, (2022), PLoS pathogens, 18
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
Datoo MS. et al, (2022), Lancet Infect Dis